Get it on Google Play

Novocure's (NVCR) Optune Approved in Japan for Glioblastoma

December 19, 2016 7:29 AM EST Send to a Friend
Novocure (NASDAQ: NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Optune® (NovoTTF-100A) – ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login